No takes yet. Share an insight, caveat, or question.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“Early lipid screening beginning at 9-11 years of age enables earlier identification of dyslipidemia, including familial hypercholesterolemia (FH), offering opportunity for intervention prior to accumulation of atherogenic exposure.”
Simulation reveals genetic testing for FH in childhood may improve CVD outcomes but is not cost-effective, suggesting a need for greater lifestyle therapy.
Bellows et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: